Therapy Areas: AIDS & HIV
Humanigen Receives Disappointing Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B
13 July 2022 - - US-based biopharmaceutical company Humanigen, Inc. (NASDAQ: HGEN) has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases' (NIAID) ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients, the company said.

The trial did not achieve statistical significance on the primary endpoint, which was defined as the proportion of patients with baseline CRP


Related Headlines